Peptide-Targeted Drug Delivery
How peptide ligands like RGD, transferrin, and folate are used to direct therapeutic agents to specific tissues, particularly tumors, for improved drug delivery.
Peptide-Targeted Drug Delivery
Peptides serve as targeting ligands that direct drugs, nanoparticles, or imaging agents to specific cell types or tissues. Their small size, low immunogenicity, and ease of synthesis make them ideal candidates for targeted delivery strategies.
RGD Peptides
The Arg-Gly-Asp (RGD) sequence is the most extensively studied targeting peptide. It binds integrin receptors (alpha-v beta-3) that are overexpressed on tumor vasculature and metastatic cells. RGD-functionalized nanoparticles accumulate preferentially in tumors through active targeting.
Mnemonic: “RGD = Really Goes to Disease” (targets tumor vasculature).
Cyclic RGD variants (cyclo[RGDfK]) show improved receptor selectivity and metabolic stability compared to linear forms. The cyclic constraint reduces proteolytic susceptibility while maintaining integrin binding affinity.
Transferrin-Based Targeting
Transferrin receptors are upregulated on rapidly dividing cells, including many cancer types. Peptides derived from transferrin or its binding domain can be conjugated to drug carriers to exploit this receptor overexpression. The transferrin-transferrin receptor complex internalizes through clathrin-mediated endocytosis, delivering cargo directly into the cytoplasm.
Folate Targeting
Folate receptors are overexpressed on ovarian, breast, lung, and colon cancers. Folic acid conjugated to peptides or nanoparticles binds folate receptors with high affinity (Kd approximately 0.1 nM). This system is particularly effective because folate is a small, stable molecule that tolerates chemical conjugation without losing receptor binding.
Tumor Microenvironment Considerations
Effective targeting must account for the tumor microenvironment:
- Enhanced permeability and retention (EPR) effect provides passive accumulation
- Acidic pH in tumors can be exploited with pH-sensitive targeting peptides
- Protease-rich environments require stabilized peptide constructs
Design Considerations
When designing peptide-targeted delivery systems, evaluate:
- Peptide stability in circulation
- Binding affinity and selectivity for the target receptor
- Linker chemistry that preserves both targeting and drug function
- Immunogenicity of the conjugate
Learning Tip
Start with the receptor expression profile of your target tissue. Match the peptide ligand to the receptor, then optimize stability and pharmacokinetics. The best targeting peptide fails if it is degraded before reaching the target.